Valuation: UCB

Market Cap 53.88B 60.47B 49.41B 44.91B 84.42B 5,714B 86.35B 591B 237B 3,024B 227B 222B 9,581B P/E 2026 *
25.5x
P/E 2027 * 21.8x
Enterprise Value 54.11B 60.73B 49.63B 45.1B 84.78B 5,739B 86.72B 593B 238B 3,038B 228B 223B 9,623B EV / Sales 2026 *
6.08x
EV / Sales 2027 * 5.23x
Free-Float
61.59%
Yield 2026 *
0.52%
Yield 2027 * 0.53%

Last Transcript: UCB

1 day+2.69%
1 week+3.64%
Current month+3.13%
1 month+44.45%
3 months+26.61%
6 months+25.63%
Current year+21.63%
1 week 275.5
Extreme 275.5
292.2
1 month 197.45
Extreme 197.45
292.2
Current year 197.45
Extreme 197.45
292.2
1 year 197.45
Extreme 197.45
292.2
3 years 65.4
Extreme 65.4
292.2
5 years 65.4
Extreme 65.4
292.2
10 years 54.84
Extreme 54.84
292.2
Manager TitleAgeSince
Chief Executive Officer 67 2014-12-31
Director of Finance/CFO 60 2020-06-30
Chief Tech/Sci/R&D Officer 59 2024-04-30
Director TitleAgeSince
Director/Board Member 55 2011-12-31
Director/Board Member 67 2014-12-31
Director/Board Member 56 2014-04-23
Date Insider Type Main position Quantity % Market Cap. Importance
1/15/26 Exercice

Executive/Senior Manager

3,000 0.0015%
1/15/26 Exercice

Executive/Senior Manager

3,000 0.0015%
1/15/26 Buy

Director

500 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+2.69%+3.64%+33.92%+318.88% 60.47B
-1.81%+2.34%+51.85%+136.20% 1,263B
-0.23%+0.36%+48.48%+82.05% 665B
-0.19%+1.14%+35.68%+108.29% 521B
-1.06%-2.49%+47.76%+65.17% 387B
-0.15%+2.64%+77.98%+43.95% 371B
-0.10%+1.38%+32.03%+59.21% 310B
+0.13%+7.59%+12.79%+36.65% 293B
-1.96%+1.81%+46.65%+71.93% 259B
-1.72%+3.64%+40.02%+111.54% 216B
Average -0.33%+5.48%+42.72%+103.39% 434.59B
Weighted average by Cap. -0.76%+5.94%+46.07%+95.65%

Financials

2026 *2027 *
Net sales 8.91B 9.99B 8.17B 7.42B 13.95B 945B 14.27B 97.62B 39.13B 500B 37.52B 36.71B 1,584B 9.91B 11.12B 9.09B 8.26B 15.52B 1,051B 15.88B 109B 43.54B 556B 41.74B 40.85B 1,762B
Net income 2.18B 2.45B 2B 1.82B 3.42B 232B 3.5B 23.94B 9.6B 123B 9.2B 9.01B 388B 2.53B 2.84B 2.32B 2.11B 3.96B 268B 4.05B 27.69B 11.1B 142B 10.64B 10.41B 449B
Net Debt 233M 262M 214M 194M 366M 24.75B 374M 2.56B 1.03B 13.1B 983M 962M 41.49B -2.02B -2.26B -1.85B -1.68B -3.16B -214B -3.23B -22.09B -8.85B -113B -8.49B -8.31B -358B
Projected Income Statement - Annual - UCB
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
26-11-05 €290.20 +2.69% 256,291
26-11-04 €282.60 +2.21% 245,301
26-11-03 €276.50 -0.58% 206,880
26-11-02 €278.10 -1.17% 220,594
26-10-30 €281.40 +0.50% 279,985
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - UCB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
282.60EUR
Average target price
291.58EUR
Spread / Average Target
+3.18%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - UCB